More breast cancer lesions were diagnosed in women with dense breasts when ultrasound screening was conducted in conjunction with mammography compared with mammography alone.
An international team of investigators is evaluating the novel topoisomerase-1 inhibitor etirinotecan pegol in patients with metastatic breast cancer, and at the same time evaluating target-specific biomarkers in CTCs.
A potential pathogenic role for the androgen receptor (AR) exists for some breast cancer (BC) subtypes according to 2 new studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2014.
An ongoing clinical trial will determine whether the addition of weekly nab-paclitaxel to gemcitabine or carboplatin improves PFS versus the gemcitabine-carboplatin doublet as first-line therapy for patients with metastatic TNBC.
Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.
William J. Gradishar, MD, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
JTT Articles
HPV Test With Genotyping Supplants Pap Test
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
Graft Versus Host Disease for the General Oncologist
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.